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1. Introduction
Miniaturized structures in computer chips have reached the 
lower nanoscale and have thereby revolutionized our world. 
Chemical synthesis is another field that is suited for automation 
and radical miniaturization. Synthesis is done by mixing different 
chemical building blocks in a solvent and in exactly defined stoi-
chiometry, while meeting additional conditions, e.g., temperature 
and reaction time. Synthesis usually starts with a planning phase 
Chemical synthesis is performed by reacting different chemical building blocks 
with defined stoichiometry, while meeting additional conditions, such as tem-
perature and reaction time. Such a procedure is especially suited for automation 
and miniaturization. Life sciences lead the way to synthesizing millions of dif-
ferent oligonucleotides in extremely miniaturized reaction sites, e.g., pinpointing 
active genes in whole genomes, while chemistry advances different types of 
automation. Recent progress in matrix-assisted laser desorption/ionization 
mass spectrometry (MALDI-MS) imaging could match miniaturized chemical 
synthesis with a powerful analytical tool to validate the outcome of many dif-
ferent synthesis pathways beyond applications in the life sciences. Thereby, due 
to the radical miniaturization of chemical synthesis, thousands of molecules 
can be synthesized. This in turn should allow ambitious research, e.g., finding 
novel synthesis routes or directly screening for photocatalysts. Herein, different 
technologies are discussed that might be involved in this endeavor. A special 
emphasis is given to the obstacles that need to be tackled when depositing tiny 
amounts of materials to many different extremely miniaturized reaction sites.
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to select suitable mechanisms and proce-
dures, followed by a trial-and-error phase. 
This was also true some 100 years ago 
when Haber[1] asked his technicians at the 
Technical University in Karlsruhe to manu-
ally mix and process thousands of different 
mixtures of nanoparticles to eventually find 
the catalyst that transforms nitrogen and 
hydrogen into ammonia—to manufacture 
the fertilizer that a fast growing population 
needed so desperately. Some 80 years later, 
the Heidelberg University spin-off company 
high-throughput experimentation (HTE),[2] 
now a subsidiary of BASF with some 
300 employees) automated Fritz Haber’s 
screening procedure by employing pipet-
ting robots and by adding a professional 
analytical pipeline made of liquid chroma-
tography (LC)-coupled and gas chromatog-
raphy (GC)-coupled mass spectrometers to 
screen for all kinds of catalysts.[2b]
Although impressive, this type of min-
iaturization only moderately increases the number of different 
chemicals that can be screened, e.g., for the novel types of fuel cell 
needed nowadays. In organic chemistry, one obstacle to more rad-
ical miniaturization has been the absence of an analytical method 
that: i) can handle very small amounts of synthesized molecules, 
and, in addition, ii) would do so for tens of thousands, maybe 
millions of reaction sites in a few minutes. There are certainly addi-
tional points on the wish list: iii) synthesized molecules should be 
analyzed quantitatively, iv) a method to follow the reaction kinetics 
would be helpful, and v) above all, synthesis sites should be 
reliably supplied with extremely miniaturized amounts of mate-
rials that are needed for chemical synthesis (chemical building 
blocks, catalysts, scavengers, acids, or bases).
Herein, we summarize recent examples that promise to min-
iaturize and automate organic synthesis, with an emphasis on 
the challenges of handling tiny amounts of chemicals in defined 
stoichiometry. In addition, recent progress in matrix-assisted 
laser desorption/ionization mass spectrometry (MALDI-MS)[3] 
imaging, which could indeed match miniaturized chemical syn-
thesis with at least one important analytical tool to validate the 
outcome of a very large number of different synthesis routes, is 
briefly discussed. If combined, automation, miniaturization, and 
analytical methods that can handle many different reaction sites 
promise to drastically reduce the efforts that are needed to find 
novel chemical synthesis pathways or even novel reaction mecha-
nisms. When mated to the material sciences, and similar to Fritz 
Haber’s screening for novel catalysts, strong economic, scientific, 
and societal interests will presumably advance these efforts.
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2. Automated, Autonomous Synthesis for Organic 
Chemistry
The (fully) automated, autonomous synthesis of organic 
molecules is a challenge that many research groups in aca-
demia and industry have tried to address for many decades. In 
comparison to the fully automated solutions in engineering, 
experimental molecule chemistry, in particular for research 
purposes or synthesis on a small scale, has never reached 
this progress in automation. In essence, there are in general 
two synergistic approaches to reach this aim: some projects 
intend to automate parts of a chemical synthesis to enhance 
the throughput of a chemistry lab; other projects aim for the 
machine-driven handling of all traditionally human-based pro-
cedures with the focus on autonomous synthesis, which does 
not necessarily have to lead to a high-throughput procedure.
2.1. Automated Combinatorial and High-Throughput Synthesis 
(of Submilligram Entities)
Automated combinatorial synthesis arose as a well-known 
procedure for half-automated synthesis of small organic com-
pounds in the 1990s. In particular, the chemical industry 
searching for large libraries of different compounds for bio-
logical screening campaigns, operated departments that were 
able to synthesize, analyze, and purify dozens of thousands of 
compounds in a few months. Combinatorial chemistry is sup-
ported and enhanced using automated systems like pipetting 
robots (liquid handlers), automated synthesis stations, auto-
mated tracking systems, automated purification stations, and 
the generation of possible libraries via virtual design. Many of 
those approaches use solid-phase organic synthesis (invented 
by Merrifield in the 1960s)[4] as a methodology to be able to deal 
with the large number of different compounds in combination 
with an easy handling of batches in special resin-containing 
vessels. As an example, systems like the IRORI technique,[5] in 
combination with the use of reaction mini blocks, have been 
shown to be efficient for the upscaling of compound numbers. 
As a result, the amount of isolated reaction product per reac-
tion had to be decreased to allow a reduction of reagent costs 
and to ensure the fast purification of the obtained compounds 
via high-performance liquid chromatography (HPLC).
While combinatorial synthesis was very successful in terms 
of synthesis of small molecules in a high-throughput manner, 
the procedure was criticized due to the low impact of the 
resulting libraries with regard to biological activity and the 
identification of novel pharmaceutical blockbusters. Therefore, 
the efforts in combinatorial chemistry have been drastically 
reduced in the chemical and pharmaceutical industry during 
the last 20 years. Only for very specific applications was combi-
natorial chemistry continued. These efforts were accompanied 
by manifold academic developments in combinatorial chem-
istry and solid-phase chemistry.[6]
Recently, modern applications[7] of combinatorial chemistry 
were presented, but unfortunately, these modern applications[8] 
suffer very often from manual handling and are not supported 
by automation techniques for chemical synthesis and compound 
purification, as demonstrated by the industry in former times.
2.2. Approaches to Fully Automated Synthesis by Robots  
(Automation Platforms)
The fully automated synthesis of compounds by the substitu-
tion of human work and handling offers many benefits with 
respect to the efficiency of chemical synthesis, safety issues, 
and reproducibility. A fully automated synthesis must cover 
all necessary steps of a synthetic procedure and should be as 
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flexible as possible with respect to the adaptation of the syn-
thetic procedure (plants in the chemical industry designed for 
large-scale production of one particular synthesis in tons are 
not considered here). Therefore, systems for a fully automated 
synthesis of pure organic compounds differ in many aspects 
from systems that focus only on high-throughput synthesis. 
High-throughput procedures, as described for the synthesis of 
large libraries of different compounds in combinatorial chem-
istry, often focus on selected reactions that are optimized to give 
the target compound classes for a variety of different starting 
materials. In contrast to the aims of a fully automated single 
reaction, the yield and purity of the single compound in a high-
throughput synthesis are less important than the generation 
of many derivatives in parallel. Another important difference 
is the scale of the reactions and the obtained products: while 
high-throughput procedures usually get along with a few milli-
grams of product or less, fully automated reaction systems and 
synthesis platforms are often designed to produce the target 
compound in multi-milligram to gram scale, offering options 
for full analysis of the compounds. Automated systems for fully 
automated chemical synthesis have been developed by compa-
nies and also in academia, while many of these systems claim 
a full automation, which is, in most cases, not given. Examples 
for partially automated chemical reactions, offering diverse 
recording and observation opportunities are, among others, 
the synthesis machines Integrity[9] or the microwave systems of 
Anton Paar[10] and Biotage.[11] Other systems for special applica-
tions are, for example, the automation systems for peptide or 
oligosaccharides synthesis (see Section 3.2), which offer, despite 
a limitation in automation processes, a good applicability to 
certain chemical procedures with less-complicated procedures. 
Systems that include liquid-handling stations, powder dosing 
modules, vial transfer options, and other options to add helpful 
modules that can be incorporated, are for example the Chem-
Speed[12] automation systems, Zinsser analytics platforms, or 
research plants from companies like Hightec Zang.[13] In par-
ticular the ChemSpeed automation platforms are widely used 
in industry and in academia, as they can be combined with 
many modules necessary for standard organic and inorganic 
chemistry. The platform itself can be modified according to the 
needs of the scientific project and can serve as a synthesis plat-
form for single reactions with detailed control of the reaction 
parameters, or can be used for the parallel synthesis of dozens 
of compounds.[14] All of the abovementioned systems suffer 
from the disadvantage that the full replacement of human inter-
action has still not been reached, as the described commercial 
platforms are still independent systems with partly flexible but 
still limited preparation, synthesis, and analysis capacity. The 
missing parts of these systems are, in general, an automated 
storage system for all chemicals, being those that are accessible 
to the scientist, and a suitable dosing station for liquids, solids, 
and oily substances. Also, these systems, in general, do not 
offer procedures that most often have to follow an automated 
synthesis, like the purification of the compounds. The purifi-
cation of the compounds is always necessary if filtering is not 
sufficient to analyze the compounds via suitable techniques 
like NMR, HPLC, or GCMS. Very impressive platforms that try 
to solve these bottlenecks of the synthesis stations have been 
developed in the past by researchers at Sanofi-Aventis.[15] The 
team in Germany installed the automation pipeline SynCar for 
automated solution-phase synthesis (10–100 mg scale) covering 
almost all aspects of common organic chemistry, like synthesis 
(temperature control and liquid-reagent handling), filtration, 
liquid–liquid extraction, evaporation, weighing, solid-phase 
extraction, and HPLC/MS analysis (Figure 1). The concept was 
realized by seven modular workstations, connected by a shuttle 
transfer. The system was suitable for a parallel treatment of 
four reactions, of which each can follow a different reaction 
workflow through the shuttle service.
Other companies also created automated systems to reach 
a fully integrated automated synthesis solution. For example, 
Lilly built a platform that covers not only most of the impor-
tant steps of an organic chemical synthesis but is also globally 
accessible via a special program. This program (Open Innova-
tion Drug Discovery Synthesis (OIDD))[16] allows other external 
researchers to propose target structures and libraries to be syn-
thesized with the remote-controlled platform. The architecture 
of the platform was constructed in a way that allows flexible 
adaptations to diverse synthesis strategies and several applica-
tions, such as the synthesis of heterocycles, like benzodiaze-
pine-diones or pyrazoles.[17] Recently, Burke and co-workers[18] 
presented a procedure for solution-phase synthesis of very 
diverse compound classes via an automated process. The con-
cept relies on the selection of reactions that allow a conversion 
in high yields via the use of building blocks, very similar to a 
combinatorial synthesis approach. The automation protocol 
Adv. Mater. 2019, 1806656
Figure 1. Automated synthesis platform SynCar. One example is shown for an automated synthesis platform developed in an industrial project. Left: 
the layout of SynCar with transfer system in red, workstations in yellow, and cabins in blue. Right: the liquid–liquid extraction module of SynCar. Repro-
duced with permission.[15] Copyright 2005, American Chemical Society.
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contains the synthetic steps of coupling, deprotection, as well 
as purification, and is fully controlled via a self-written script. 
While Burke and co-workers use a cartridge-based system based 
on commercially available plastic cartridges for almost all steps 
of the preparation, synthesis, and purification, approaches from 
Cronin and co-workers[19] focus on the use of common glass-
ware and standard equipment of a chemistry lab or a redesign 
of common glassware by 3D printing. Automated solutions for 
the manufacture of fine chemicals and pharmaceuticals in a 
self-contained plastic reactionware device were successful. A 
chemical to computer-automated design (ChemCAD) approach 
was used, which translates bench-scale synthesis into a plat-
form-independent digital code. Additionally, printed devices 
were constructed that manage the operation of the synthetic 
route internally via simple operations. This approach was 
demonstrated for the γ-aminobutyric acid receptor agonist 
(±)-baclofen, which was synthesized in a three-step synthesis 
procedure including five modules (Figure 2a–e).[20] The reac-
tion modules cover: a) a module for a Michael addition, com-
bined with evaporation and ether extraction; b) a module that 
combines solvent exchange and a reduction step; c) a module 
for phase separation and filtration; d) a module for solvent 
exchange and hydrolysis; and e) a module for a final filtration 
step. The overall procedure includes processes to add reagents 
in solution (by Luer syringes), the stirring of the reactions with 
PTFE-coated stirring bars, and cooling or heating of the reac-
tions in the cartridges via transfer of the reaction vessels to an 
ice or a sand bath on a stirring hotplate.
In another example, Cronin and co-workers constructed 
an automated synthesis robot by modifying an open-source 
3D-printing platform. The resulting automated system was 
used to print polypropylene reaction vessels of differing internal 
volumes and subsequently make use of these fabricated vessels 
to synthesize the nonsteroidal anti-inflammatory drug ibu-
profen via a consecutive one-pot three-step approach.[19] The 
same group could show some interesting examples to apply 
automated synthesis procedures to a parallel reaction mode.[21] 
The development of a networked reaction station consisting of 
up to four simple and affordable (<$500) robots was demon-
strated. The robots were built with a standard set of hardware 
and software protocols that can be networked to coordinate 
chemical experiments in real time using a cloud-based worksta-
tion. During the last years, automation technologies attracted 
more and more attention in organic synthesis for materials 
Adv. Mater. 2019, 1806656
Figure 2. Concept of the cartridge-based solution of Cronin and co-workers shown for the synthesis of baclofen. The identified synthetic processes are 
split into different modules (a–e), which are used as model for the fabrication of cartridges in which the reaction steps and further steps like separation 
processes take place. Reproduced with permission.[20] Copyright 2018, AAAS. The reaction scheme is newly drawn according to ref. [20].
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science. Also, researchers coming from physics are interested 
in the design of chemistry automation, as this might accelerate 
breakthroughs in research areas like organic light-emitting 
diode (OLED) construction and photovoltaics, only mentioning 
two particular applications.[22] Hein,[23] Aspuru-Guzik,[24] and 
Berlinguette[24] and their co-workers demonstrated smart solu-
tions to design concepts for materials development via AI, 
combined with automation technologies in chemistry and auto-
mated analysis tools focusing on materials development. Their 
concept of a materials acceleration platform (MAP)[24] aims for 
the establishment of self-driving laboratories that may solve key 
questions in materials design by combining the most impor-
tant steps for new developments. As not all developments can 
be highlighted here, we refer to additional reviews for further 
reading.[25]
2.3. Automated Synthesis by Flow Chemistry
Flow chemistry offers different advantages for the automation 
of chemical synthesis in contrast to traditional flask chemistry. 
First of all, processes in flow chemistry are very often digitally 
controlled and the systems are connected to sensors. As most 
of the processes take place in tubes and coils or miniaturized 
reactors and are connected by valves, no special hardware 
needing manual handling or adaption of automated transfer 
by grippers is required. Additionally, the scale-up is facilitated 
in continuous flow chemistry, which makes it a very useful 
alternative to common flask chemistry especially in the chem-
ical industry. Many processes for automated reactions via flow 
chemistry have been published, describing one-step syntheses, 
that are used for the synthesis of many different compound 
types and reaction classes[26] in academia (see publications 
of the key players and their co-workers[27]) and in industry.[28] 
Missing key steps of these approaches are in almost all cases 
procedures belonging to the chemical-synthesis workflow, like 
preparation of the reactants (dissolution) and the purification 
of the resulting compounds. However, the combination of dif-
ferent techniques recently allowed also complex, multistep 
syntheses. It is beyond the scope here to comprehensively sum-
marize all of them, but some highlights of the current literature 
are given in the following paragraph.
As one example, the use of Cu-pipes as the catalytic medium 
for a Cu-catalyzed alkyne–azide cycloaddition (CuAAC) reaction 
yielding triazoles was shown as an interesting example for flow 
chemistry recently.[29] The authors could show that the use of 
Cu-pipes yielded the target compounds with very low content of 
Cu, which allowed use in biological systems that are sensitive 
to the amount of copper impurities usually obtained in CuAAC 
reactions. Flow reactions have also been applied to low-temper-
ature reactions that are needed for individual processes within 
one reaction, like cooling and the addition of further reagents. 
A recent example was presented by Newby et al. who com-
bined several flow reactors to a continuous flow chemistry plat-
form allowing the subsequent reaction of organic compounds 
with temperature-sensitive organometallic reagents followed 
by the reaction with an electrophile.[30] The procedures were 
applied, for example, to the synthesis of a 20-compound library 
of polysubstituted, fluorine-containing aromatic substrates. 
In particular, photochemistry is suitable for application in flow 
synthesis,[31] as several examples for fast reactions in small reac-
tion (irradiation) volumes[32] or applications to reactions with 
visible-light laser sources for flow-chemistry-integrated vessel 
reactors show.[33] Although, many flow reactors need chemical 
engineering to solve chemistry-related synthesis challenges,[34] 
photochemistry-based flow reactors are also commercially avail-
able,[35] allowing a practical ready-to-use automation in chem-
istry labs. Systems, including the purification of the obtained 
products are very beneficial in terms of a full automation of a 
chemical procedure. The purification is particular important 
for compounds that are used for materials sciences, which are 
very sensitive to impurities. A downstream processing in a flow 
reactor or platform representing the processing in a routine 
chemistry lab (e.g., the purification of the obtained compounds) 
is therefore very important. Examples for purification tech-
niques based on phase separation were recently demonstrated 
by Lévesque et al.[36] In-line techniques for the purification of 
aryldiazomethanes were used to allow their direct application 
in subsequent reactions. In the latter case, the target reagents 
needed to be deprotected in situ from stable sulfonylhydrazones 
and needed to be reused directly, as they are often unstable and 
toxic. The purification was established by an aqueous washing 
step yielding a clean and base free diazo target compound. 
Another approach was shown by Dai et al., who reported the 
synthesis of atropine, including the separation of the target 
compound from several by products with structural similarity 
to atropine. The purification of atropine to >98% purity was 
achieved by pH control in three sequential liquid–liquid extrac-
tions and a functionalized resin.[37] As this is true for an auto-
mated procedure in general, flow-chemistry approaches allow 
the highest benefit, if several steps can be done sequentially. 
Some platforms indeed enable a combination of several reac-
tors without the need of manual interaction.[27j,28b,38] Examples 
for those multistep reactors or platforms are known for phar-
maceutical applications, but, if the system offers flexible reac-
tion modes, the use for other applications such as in materials 
science is, in principle, possible. A very impressive example for 
an automation of flow-chemistry processes for the synthesis of 
complex molecules was shown by the DARPA project SynFini 
realized by SRI international.[39] The developed platform auto-
mates the design, reaction screening, and optimization (RSO), 
as well as the production of the target molecules. The platform 
is a nice example how synthesis can work, if several parts of the 
chemist’s activities are combined in an automated workflow. 
The heart of the platform is a benchtop multistep synthesizer 
(AutoSyn) that can reproduce many different reaction routes, 
which are based on solution-phase chemistry. AutoSyn is com-
posed of unit operation modules to accomplish reagent delivery, 
mixing, heating, cooling, separation, and analysis. Other exam-
ples of multistep reactions showed the compatibility of batch 
synthesis with flow synthesis as an example for a flexible 
approach to combine the best methods for each synthetic pro-
cedure in a multistep reaction.[40] The platform was developed 
by Fitzpatrick and Ley, who applied open-source technologies 
to automate, control, and monitor the individual process in the 
batch or flow part of the synthesis. They also showed how other 
standard laboratory tasks of a chemical synthesis, like contin-
uous extraction and solvent switching steps, can be included in 
Adv. Mater. 2019, 1806656
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such a platform. Although the procedures and opportunities of 
flow-chemistry applications already have a high impact in syn-
thetic chemistry and allow a high level of automation for the 
production of a wide range of compound types, drawbacks of 
many single-step continuous-flow systems and multistep sys-
tems are, for example, missing steps for: 1) the preparation of 
the reactants (dissolution) and 2) comprehensive methods for 
the purification of the intermediates or resulting compounds, 
such as chromatography. In addition, automation in flow 
chemi stry is applied mainly to pharmaceutical synthetic chal-
lenges, while materials science, being a suitable application for 
existing automation techniques, has almost not benefited at all 
from the flow technologies so far.
2.4. Scope of Artificial Intelligence on Automation 
in Chemical Synthesis
Many automation procedures are nowadays combined with 
artificial intelligence (AI) to enhance the productivity of the 
designed systems. A combination of AI and automation is very 
beneficial, in particular in those cases where either, even auto-
mated chemical synthesis, is time consuming and expensive or 
the analysis of high-throughput procedures cannot be managed 
by humans. AI is used for the analysis of the synthesis result 
and is also used for reaction design and compound selection. 
Many procedures have been developed and applied; among 
them are computer-aided reaction design, and reaction predic-
tion based on high-level quantum chemical methods, machine 
learning for retrosynthesis, and product prediction. Different 
models for the optimization of chemistry processes have been 
described recently. Zare and co-workers describe the optimiza-
tion of chemical reactions by deep reinforcement learning, to 
obtain the optimal reaction conditions in microdroplet reac-
tions;[41] meanwhile, deMello and co-workers presented a con-
strained optimization procedure for self-optimizing reactors 
that are trained to produce certain target compounds in par-
allel to suppressing the formation of unwanted by products.[42] 
Aiming for the generation of self-driving chemistry laborato-
ries, Aspuru-Guzik and co-workers showed the use of Phoenics 
and Chimera in the context of chemistry and experimenta-
tion. Phoenics, a probabilistic global optimization algorithm, 
was used to identify the set of conditions of an experimental 
chemical reaction by proposing conditions and updating of 
those proposed conditions after the experimental feedback to 
Phoenics.[43] Chimera was used as a multitarget optimization 
method for automation techniques like the autocalibration of a 
virtual robotic sampling sequence for direct injection.[44] Cronin 
and co-workers[45] presented an example to predict the reactivity 
by a reaction system that is controlled by a machine-learning 
algorithm. The machine-learning system was able to predict 
the reactivity of about 1000 reaction combinations with accu-
racy higher than 80%. A similar approach[46] demonstrated the 
design of an autonomous reaction network that included the 
evaluation of the reactions’ outcome by in-line spectroscopy 
and real-time feedback and analysis with an algorithm that 
is able to distinguish and select the most reactive pathways. 
Machine learning was proven to be very suitable to allow alter-
natives to human experience and expertise for a fast suggestion 
of a possible reaction outcome or the suggestion of the right 
starting materials and conditions for reaction design and ret-
rosynthesis. During the last few years, different procedures 
have been proposed, including work of the group of Jensen,[47] 
Baldi,[48] Doyle,[49] and Waller,[50] and their co-workers. The most 
prominent approach was contributed by Waller and Segler, who 
developed a template-based machine-learning model using the 
training of a neural network with chemical fingerprints. As the 
dataset, 3.5 million curated reactions of the Reaxys database 
were used. The reaction data were translated via the creation of 
extended connectivity fingerprints (ECFP) in machine-readable 
input formats for a neural network. The training of the neural 
network was done with the help of reaction rules that were 
extracted algorithmically (for details for the automatic genera-
tion of reaction rules please, see the information in ref. [51] 
and references therein). Retrosynthetic challenges are then 
submitted to the system with the fingerprint of the reaction 
product (see Figure 3a). By using the previously trained neural 
network, the fingerprint is then assigned to the most relevant 
reaction rules, which, in consequence, define the necessary 
starting materials. The use of fingerprints for the training of 
the neural network and the retrieval of the retrosynthetic infor-
mation enables the system to learn the context (e.g., functional 
groups) of the applied rules (Figure 3b). If the procedure is 
applied successively to all starting materials that are identi-
fied by a retrosynthetic approach, the procedure of Waller and 
co-workers can be used to design a full retrosynthetic multistep 
procedure. Such an example was shown by the reconstruction 
of a recently published synthetic procedure, for that the theo-
retical retrosynthesis pathway was fully reconstructed by a step-
by-step prediction of the most probable reaction rules for each 
step (Figure 3c).
The authors combined their previously developed proce-
dure[51] (applied to 12.5 million reactions) with additional AI in 
form of a Monte Carlo tree-search model to build a filter net-
work to preselect the most promising retrosynthetic steps.[50]
Also, large companies invest in machine-learning applica-
tions for chemists and offer developments to the community. 
Recently,[52] IBM launched a seq2seq-based machine-learning 
approach based on a training of their network with a patent 
dataset of 2 million reactions. The results of the project are 
offered as a web application in the IBM cloud. So far, the appli-
cation of machine learning, independent of the applied neural 
network is not a suitable method to invent reactions or to plan 
reactions beyond the established knowledge. Options to achieve 
such an ability were proposed by an approach to model chem-
ical reasoning.[53] The method uses a formalism for reaction 
prediction to find missing links in a knowledge graph. A knowl-
edge graph, containing 14.4 million molecules and 8.2 million 
binary reactions, was created, allowing generalization beyond 
known reaction types, and is thus capable of discovering novel 
transformations within an experimentally shown similarity of 
reaction behavior.
3. Miniaturized Synthesis and Molecule Libraries
Miniaturization in organic chemistry means from a technical 
point of view: tiny amounts of different materials must be 
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reliably deposited at many different reaction sites, in exactly 
defined stoichiometry, and in a suitable formulation, before 
these molecules are reacted. All these tiny reaction mixtures 
should not decay over time and start and stop their reactions 
at defined time points. Moreover, they should not be snatched 
away by absorbing surfaces. Clearly, the smaller the reaction 
sites, the more challenging these tasks are. Finally, miniatur-
ized synthesis must be matched by suitable analytical tools.
Life sciences have been the drivers in the invention of 
high-throughput methods that came along with miniaturi zed 
chemi cal synthesis. Sparked by Merrifield’s invention of solid-
phase synthesis of peptides,[4a] the automated synthesis of bio-
molecules such as oligonucleotides,[54] peptides,[55] and oligo-
saccharides[56] was developed. In parallel, the question arose of 
how to handle a large number of such molecules in meaningful 
scientific experiments. It was Ekins[57] who advanced the con-
cept of the “array” in the mid 1980s with an argument that is 
still valid today: Driven by Brownian motion, an antibody, or 
any other molecule that binds to another molecule, will probe a 
potential binding partner similar to a key that tests a lock. Only 
if the “antibody key” exactly fits to the “binding molecule lock”, 
these two molecules come close enough to develop hydrogen 
bonds, electrostatic, hydrophobic, or van der Waals forces. 
Then, these exert mutual attraction over very short distances, 
and binding ensues. Moreover, if one binding partner is teth-
ered to a known position on the 2D surface, then the site where 
binding is detected immediately informs the experimenter 
about the type of molecule that did the binding. The revolu-
tionary nature of this concept is based on the fact that a binding 
antibody or deoxyribonucleic acid (DNA) molecule would probe 
not just one, but rather thousands, or even millions of arrayed 
molecules in a single experiment. Ekins’ concept convinced 
Boehringer Mannheim (now Roche Diagnostics) to develop 
such arrays, but these arrays never materialized as a commer-
cial product. Obviously, too many resources were needed to 
synthesize thousands of different molecules and reliably spot 
and link them to a 2D-support in an array format.
More successful proved to be strategies for the in situ 
synthesis of oligonucleotides,[58] oligosaccharides,[59] and 
peptides.[60] While Ekins had to individually synthesize 
and handle thousands of different molecules, in situ syn-
thesis drastically reduced these efforts by using only a small 
number of building blocks. Especially successful proved to 
be strategies for the synthesis of oligonucleotides[58]and pep-
tides,[60] while the large-scale in situ manufacturing of a third 
important biological class of molecules—oligosaccharide[59] 
arrays—is still challenging. The basic idea in all of these 
methods is to do highly parallelized solid-phase synthesis 
in many different drastically miniaturized synthesis sites on 
a 2D support. The main technical difficulty in all of these 
methods is to reliably supply these many separated miniatur-
ized reaction sites (“spots”) with tiny amounts of different 
monomers to elongate the growing oligomers with “their” 
monomers. This was done by using different printing tech-
niques,[61] or by using lithography[62] to define those reaction 
sites.
It should be noted that quality control in array synthesis is 
still problematic. Usually, the amount of synthesized molecules 
(pmol–fmol) per spot is too small for most of the standard anal-
ysis methods. In this respect, the invention and commercializa-
tion (Shimadzu, Bruker, Applied Biosystem) of matrix-assisted 
laser desorption–ionization (MALDI)[63]–mass spectrometry 
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Figure 3. Automated retrosynthesis via the application of neural networks. a,b) Schematic description of the procedure to gain realistic retrosyn-
thetic procedures and necessary starting materials. c) Example showing the capability of the presented procedure with a published synthetic strategy 
according to ref. [51a]. a–c) Reproduced with permission.[51b] Copyright 2019, Wiley-VCH.
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(MS) imaging[64–66] was a milestone for the quality control of 
synthesized molecules in the array format.
3.1. Synthesis of Oligonucleotide Arrays
In the 1990s, the human genome project revealed the exist-
ence of some 20 000 different human genes, and immedi-
ately the question arose as to which ones of these genes were 
active when comparing, for example, a tumor cell to a normal 
cell. DNA arrays were obviously the tool to answer this type of 
crucial questions. All you had to do was to collect messenger 
ribonucleic acid (mRNA) from the different cells, and hybridize 
labeled mRNA (or, for technical reasons, complementary DNA 
(cDNA)) to arrayed DNA spots that represent aforementioned 
20 000 human genes.[67] These mRNA molecules would then 
automatically find their complementary DNA on the array to 
reveal, in one single experiment, which ones of these genes 
were transcribed to mRNA. Experiments of this type coined the 
word “genomics,” which was meant to reveal the activity of the 
whole genome, for example, to find those genes that were only 
active in a certain cell type.
Southern[68] was the first to synthesize a dense oligonucle-
otide array by repetitively spotting the four different building 
blocks for DNA synthesis onto a microscope slide that was 
functionalized with an aliphatic linker containing a free hydroxy 
group (Figure 4). They used the phosphoramidite method[69] 
for their highly parallelized solid-phase synthesis method, 
which allowed them to miniaturize synthesis sites down to a 
spot diameter of ≈0.9 mm. Only three steps (coupling of the 
four different β-cyanoethylene phosphoramidite, oxidation, and 
detritylation) were necessary for the coupling of one monomer 
Adv. Mater. 2019, 1806656
Figure 4. A) Printing versus B) lithographic synthesis methods.[62a] In all of the printing methods, such as inkjet printing, individual synthesis sites 
(e.g., hydrophilic reaction areas on a hydrophobic surface, to confine chemicals) are supplied with tiny amounts of the different building blocks that 
are needed for array synthesis, while lithographic methods, e.g., consecutive micromirrors (left) or lithographic masks (right) are used to deprotect 
the molecules (chain of spheres: immobilized molecules, rhomb: protecting group) in the synthesis to define 1st, 2nd … n sites that are all reacted at 
once with one type of building block.
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layer, which drastically reduced the resources that were needed 
to generate a high-density array.
Shortly afterward, in 1991,[62a] the Fodor group developed an 
even more radical approach to miniaturize individual synthesis 
sites with spot sizes down to the low-micrometer range. They 
used lithographic masks—that were known from computer-
chip technology—to illuminate selected areas with ultraviolet 
(UV) light in order to remove UV-sensitive protecting groups 
in those illuminated areas. This elegant approach allowed them 
to circumvent the basic problem that comes with any type of 
miniaturized parallel synthesis of many different chemicals, 
namely how to supply individual synthesis sites with “their” 
building blocks. They simply reacted all of these deprotected 
sites at once with one of the building blocks for array synthesis, 
and afterward defined second sites that were reacted with 
another monomer (Figure 2). However, this elegant approach 
comes at a cost: these lithographic methods can always couple 
only one type of chemical to lithographically defined synthesis 
sites, which means that 20 × 15 = 300 coupling cycles and the 
same number of expensive lithographic masks are needed to 
synthesize an array with 15meric peptides with its 20 different 
amino acid building blocks. Moreover, such a large number of 
processing steps certainly hamper the quality of synthesized 
arrays due to the accumulation of unwanted side reactions.
Indeed, although Fodor and co-workers[62a] demonstrated 
their seminal approach by synthesizing very high-density pep-
tide arrays, they used only a very limited number of amino 
acid building blocks to synthesize quite short peptides. In 
order to attenuate this basic drawback of lithographic synthesis 
methods, the Fodor group and their spin-off company Affym-
etrix shifted to the synthesis of oligonucleotides that were made 
of only four different building blocks. In 1994[70] Affymetrix 
used this technology to generate first octanucleotide arrays 
(256 octanucleotides; 157 molecules per 1 cm2) that were 
hybridized to single-stranded DNA.
Soon afterward, this company commercialized very high-
density oligonucleotide arrays with up to ≈1 million octanucleo-
tides per 1 cm2. The standard length of these oligonucleotides 
was limited to 25 bases, probably due to the modest yield in 
each synthesis circle during the light-induced deprotection 
step. Still, this was a major technical breakthrough and a big 
commercial success. The biggest manufacturer of oligonu-
cleotides—Illumina Inc.—reported revenues of $666 million 
for the year 2009.[71] These sales from Illumina and Affym-
etrix reflect the many different types of scientific questions 
that could be answered by high-density oligonucleotide arrays: 
they were used in sequencing,[72] gene-expression analysis,[73] 
transcription factor binding analysis,[74] and genotyping.[75] It 
should be noted that this type of array could be used to syn-
thesize complete genomes that are assembled by PCR. Further 
information can be found in the reviews of Bumgarner[58a] and 
Heller.[76] In recent years, sales of oligonucleotide arrays were 
replaced by next-generation sequencing, which, in a sense, 
is also an example of extremely miniaturized and highly par-
allelized chemical reactions. These techniques are reviewed 
elsewhere.[77] It should be noted that many additional devel-
opments were needed to make these very high-density arrays 
a commercial success. Extremely miniaturized synthesis sites 
necessitated the development of fluorescence scanners that 
could analyze millions of very small spots that were labeled 
with fluorescently labeled cDNA. Meanwhile, several compa-
nies developed scanners with a resolution that is compatible 
with synthesis sites as small as 500 nm (e.g., Innopsys 1100,[78] 
GeneChip Scanner,[79] and SureScan Dx Microarray).[80]
Also, the quality of lithographically produced arrays was 
insufficient due to the low cleaving efficiency of light-sensitive 
protecting groups. The group from Gao were the first to pub-
lish a practical solution. They added a photoacid to “translate” 
the incoming UV light into a local acidification, which allowed 
them to replace the photolabile protecting group with its noto-
rious low cleaving efficiency (α-methyl-2-nitropiperonyl)oxy]car-
bonyl (MeNPOC)) with an acid-cleavable group that had been 
used for many years in standard solid-phase synthesis (dimeth-
oxytrityl (DMT)). Xeotron, later Invitrogen, commercialized this 
type of array. Pellois and co-workers[81] adapted this principle 
for the synthesis of peptide arrays by using a tert-butyloxycar-
bonyl (Boc)-group.
Yet another drawback was the large number of expensive lith-
ographic masks that were needed to define synthesis sites for 
each building block and for all of the coupling circles. In 2002, 
Nuwaysir and co-workers[82] used an array of switchable micro-
mirrors to illuminate selected areas with UV light, which made 
expensive lithographic masks redundant. This maskless photo-
lithographic approach allowed them to synthesize ≈80 000 
oligonucleotides per cm2. Roche NimbleGen[83] commercialized 
such arrays with up to 2.1 million synthesized oligonucleotides 
per wafer.
Also, the printing method that was invented by Edwin 
Southern was considerably advanced in the following years. 
Blanchard and co-workers[84] used inkjet printing to synthe-
size oligonucleotide arrays via the standard phosphoramidite 
method. They generated high-density oligonucleotide arrays by 
confining individual synthesis sites with the help of a hydro-
phobic/hydrophilic pattern on the solid glass slide support that 
was used to grow the oligonucleotides. Thereby, the four dif-
ferent phosphoramidate building blocks could be printed into 
hydrophilic areas without diffusing them to neighboring reac-
tion sites (Figure 2). In 2001, Hughes and co-workers[85] pub-
lished a second-generation inkjet oligonucleotide synthesizer 
that allowed him to synthesize ≈1300 oligonucleotides per 
1 cm2, which was commercialized by Rosetta Inpharmatics.[86] 
Moreover, the inject technology (POSaM arrays) was used from 
Lausted and co-workers in 2004, to generate 10 000 molecules 
per microscope slide.[87] Meanwhile Agilent offers high-quality 
inkjet-printed oligonucleotide arrays with ≈1 million different 
oligonucleotides per glass slide[88] (≈100 000 oligonucleotides 
per cm2, with an estimated 50 attomoles per reaction site.[89] If 
compared to lithographic synthesis methods, these arrays fea-
ture longer oligonucleotides with up to 100 bases, presumably 
due to the fact that all the printing techniques do not have the 
technical drawback of reacting one building after the other, but 
rather do it for all of them at once.
3.2. MALDI-MS-Based Analysis
While the binding of labeled DNA is easily detected with a 
fluorescence scanner, a chemist certainly prefers to use more 
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sophisticated methods for analysis. The invention of MALDI-
MS imaging and the development of commercially available 
machines was a milestone in this respect. These machines 
can be used to find out the precise masses of synthesized 
molecules in high-density array format,[90] and in formidable 
sensitivity (Figure 5). MALDI requires a matrix material to 
absorb the incoming laser light that causes the ionization of the 
molecules. Moreover, the solid support should be conductive 
to avoid artifacts due to light-induced charging. Synthesized 
molecules must be cleaved from the solid support to detect 
them by MALDI, which was done, for example, with a photo-
linker.[91] Due to the low cleavage rate, different groups have 
tried to carry out MALDI-MS imaging without employing such 
linkers. Su and Mrksich[92] synthesized arrays on a gold surface, 
where the relatively weak covalent bond via oligoethylene thi-
olates is directly cleaved through laser irradiation. This method 
is known as self-assembled monolayers and desorption–ioniza-
tion mass spectrometry (SAMDI).[93] Beloqui and co-workers[94] 
developed a variant of this method on indium tin oxide (ITO) 
glass. They immobilized the molecules via a noncovalent biden-
tate lipid linker that interacted with hydrophobic chains on the 
ITO glass. However, MALDI gives no definitive information 
about product purity and product distribution. LeProust and 
co-workers[95] used a phosphorus-32 (32P) gel electrophoresis of 
the cleaved oligonucleotides to provide product distribution.
In addition, MALDI-MS imaging can also be used to find 
out the masses of the binding molecules, while a fluorescently 
labeled DNA would only deliver the information that a labeled 
molecule is detected. In 1996, Köster and co-workers[97] used 
MALDI to determine the masses of bound DNA molecules that 
were hybridized to a DNA array. In this type of analysis, mass 
spectrometry was used for sequencing;[98] for example, exons of 
the p53 gene and for genotyping.[99] In 2003, Cheran et al.[100] 
used imaging time-of-flight secondary-ion mass spectrometry 
(TOF-SIMS) for the recognition of the spatial distribution of 
DNA strands. Meanwhile, MALDI-MS imaging is the method 
of choice in obtaining much of information for many different 
reaction sites.
Indeed, Lin and co-workers[3d] used plate-based microreac-
tors to prove that MALDI-MS can be used to validate the out-
come of many chemical reactions that were miniaturized down 
to the nanomole scale. They employed four different catalytic 
reactions to react 192 different N-heterocycle-containing aryl 
bromides with 192 different secondary amines in 1536 experi-
ments and in nanomole scale. They showed that the yield of 
this nanomole-scale synthesized product can be reliably quan-
titated by MALDI-MS by comparing it to a known amount of 
added standard (deuterated reaction product). Next, they added 
closely related reaction partners to determine in 1536 experi-
ments an influence of the added reagents on the synthesis yield, 
and once again employing the internal standard. Thereby, they 
could quantitate a “poisoning effect” of added molecules. How-
ever, Lin and co-workers had a much more ambitious goal: they 
wanted to do simple prescreens with many different reaction 
partners and in drastically miniaturized chemical reactions to 
find out which ones would or would not yield a product. Espe-
cially, the unproductive chemical reactions (“the dark space of 
chemical reactions”) are largely missing in the literature, but 
they are surely needed to train programs that predict prom-
ising synthesis routes, or, more simple, to avoid the design of 
synthesis routes that are doomed to failure. Obviously, it does 
not make sense to synthesize thousands of different deuter-
ated standards to do as many miniaturized chemical reac-
tions. Therefore, Lin and co-workers used only one internal 
standard to correct, for example, for losses during handling. 
They performed four different catalytic reactions to synthe-
size molecules and they painstakingly compared the strength 
of the reaction product signals in MALDI-MS versus UV-spec-
troscopy quantification of chromatography-purified reaction 
products. As expected, the signals in MALDI-MS did not match 
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Figure 5. MALDI-MS imaging and SAMDI-MS.[96] A laser scans a 2D molecule array surface, and m/z-spectra for every position on the array are gener-
ated. A) To-be-analyzed molecules in spot (S1) (blue) or S2 (red) either have to be cleaved from a linker (gray sphere) without lateral diffusion from 
the solid support before the measurement to receive spatially resolved spectra, or B) the functionalized (yellow spheres, e.g., polysaccharide) alkanethi-
olates (blue spheres), which were bound via a thiol (green sphere) group to the gold surface, can be directly cleaved via laser during the measurement 
due to lower binding energy of thiol-groups to gold surfaces.
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exactly to UV-spectroscopy-based quantification of the same 
sample, but, by defining a pass/failure threshold (20% average 
MALDI signal), they could indeed correlate MALDI signals 
to failed versus productive synthesis. In other words, Lin and 
co-workers showed that indeed MALDI-MS can be used to 
explore the chemical space with the help of miniaturized chem-
ical reactions.
3.3. Glycan Array Synthesis
Oligosaccharides are biomolecules with an important role in 
living organisms, such as cell recognition and cell adhesion.[101] 
However, their functions are barely studied, due to the difficul-
ties to synthesize them. In the 1970s the solid-phase synthesis 
of oligosaccharides was developed.[102–104] In 2014, Seeberger 
and co-workers commercialized an automated synthesizer that 
was based on a peptide synthesizer (Glyconeer 2.1).[105] This 
machine enabled the automated synthesis of single glycans 
(up to a 50mers), and, thereby, made complex glycans accessible 
to the scientific community. These aspects were reviewed by 
Wen and co-workers and Panza and co-workers in 2018.[56b,106] 
For the synthesis, Seeberger and co-workers[107] used a man-
nosyl phosphate with a temporary C6 fluorenylmethoxycarbonyl 
protecting group (Fmoc), while benzoyl groups (Bz) served as 
permanent protecting group for hydroxy groups (1 in Figure 6). 
Similar to peptide synthesis, the growing oligomers were 
immobilized on a solid-phase resin. Repetitive glycosylation via 
trifluoromethanesulfonic acid trimethylsilyl ester (TMSOTf) in 
DCM (low temperature) and Fmoc-deprotection via piperidine 
in DMF resulted in the synthesis of polysaccharides (Figure 6).
After the generation of the desired chain length, the pro-
tecting groups were removed, and the product was cleaved 
from the solid support. In 2003, Calin and co-workers[108] demo-
nstrated the synthesis of a 30mer mannoside by this method.
Similar to DNA-arrays, glycan-arrays can be synthesized in 
situ or with presynthesized glycans by contact or noncontact 
printing. This procedure is laborious, but the in situ synthesis 
of glycan arrays is still challenging. Moreover, pure glycans are 
certainly preferred to study interactions,[59b] which requires 
either high synthesis yields on the surfaces or a final purifica-
tion of the glycans on the array generated in situ.
In 2002, Wang et al. printed glycan arrays with ≈20 000 spots. 
These oligosaccharides were immobilized on glass surfaces[109] 
or nitrocellulose membranes[110] by hydrophobic interactions. 
Adams and co-workers[111] and Fukui and co-workers[110] syn-
thesized glycan arrays to study the protein–glycan interactions 
that are relevant for the scrutinized infectious disease.[112] For 
the immobilization on the surfaces, different covalent linkage 
methods were used,[113] for example, aldehyde/hydrazide chem-
istry,[114] maleimide/thiol chemistry,[115] and amino/N-hydroxy-
succinimide (NHS) ester or amino/epoxy chemistry.[116]
Fluorescence spectroscopy and MALDI were chosen not 
only for the quality control of the glycan synthesis, but also to 
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Figure 6. Automated synthesis of α-(1,6)-polysaccharides (4): a) 1, TMSOTf, dichloromethane (DCM), −15 (45 min) −0 °C (15 min); b) Fmoc-depro-
tection of 3: piperidine in DMF, 25 °C, 5 min; c) cleavage: hν, DCM; sodium methoxide (NaOMe), methanol (MeOH); Pd/C, H2, H2O. (Bu = Butyl: 
Cbz  =  benzyloxycarbonyl).
www.advmat.dewww.advancedsciencenews.com
© 2019 Karlsruhe Institute of Technology, IMT. Published by WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim
1806656 (12 of 23)
detect binding molecules. Numerous groups have used MALDI 
to investigate the interactions of proteins to glycans immobi-
lized on arrays[94,117] and also to measure enzyme activity; for 
example, studies with glycosyltransferase on an array.[94,118,119]
In 2008, Ban and Mrkisch[96] synthesized in situ an oligosac-
charide array on a robust gold surface to study enzyme activity. 
The surface was functionalized with an alkanethiolates with 10% 
phenol groups to couple the first building block. The monomer 
was activated as trichloroacetimidates for the immobilization 
on the surface and contained a temporary C5 levulinate (Lev) 
group. The remaining hydroxy groups were protected with 
acetyl (Ac) groups. The repetition of the two steps: glycosylation 
and Lev group deprotection via hydrazine allowed the synthesis 
of the oligosaccharide. The deprotection of the base-labile 
groups and the cleavage of the product were done via sodium 
methoxide. The discovery of SAMDI (Figure 3) enabled the 
direct reaction control after each coupling step. However, the 
method certainly needs to be optimized further, as the configu-
ration of the anomeric coupling is not easily predetermined.
3.4. Peptide and Protein Arrays
Life sciences have been the drivers in the development of oli-
gonucleotide arrays, and a similar desire to analyze millions 
or even billions of different proteins or peptides for biological 
activity has motivated scientists to advance techniques that 
would satisfy this desire. Indeed, proteins fulfill most of the 
tasks in a living organism, for example, as transporters, anti-
bodies,[120] structural elements,[121] and catalysts[122] and in DNA 
replication.[123] Usually, the first step toward a better under-
standing of these biological functions is to study protein–pro-
tein interactions. Again, Ekins’ concept of the array has guided 
many researchers. Büssow and co-workers[124] were the first 
to grow bacteria that expressed protein fragments on nitrocel-
lulose sheets to generate protein arrays. Bacterial clones were 
simply lysed, and no further purification was done to enrich the 
expressed protein fragments. The simplicity of this method comes 
at a cost: the expressed proteins must compete with the host’s 
proteins for binding on the nitrocellulose. Moreover, human 
serum antibodies must be preabsorbed with Escherichia coli  
proteins to remove anti-E. coli antibodies. Zhu and 
co-workers[125] modified this approach by growing bacterial 
clones that each expressed a different yeast protein in 96-well 
plates. Thereby, 5800 yeast open reading frames were expressed 
(93,5% of the total genome), and the expressed proteins were 
purified with the help of an N-terminally fused GST tag. They 
used these “purified protein microarrays” to screen for calmo-
dulin and phospholipid-interacting proteins. Crompton and 
co-workers[126] produced similar arrays to display 1200 from a 
total of 5400 proteins from Plasmodium falciparum, the causa-
tive agent of malaria. When they stained these arrays with 
≈200 different malaria sera they found a stunning number of 
491 immunogenic proteins (≈40% of tested proteins reacted 
with at least one serum). Interestingly, when Jaenisch[127] and 
co-workers stained high-density arrays with P. faliciparum-
derived peptides, they also found a very high percentage of 
immunogenic peptides, which might explain the observation 
that many malaria patients have considerably elevated levels of 
IgG antibodies in their blood—obviously this pathogen reliably 
re-infects humans, although it induces a plethora of different 
antibodies that are directed toward the erythrocyte stage of the 
pathogen. Meanwhile, the Arrayit[128] corporation offers arrays 
that display >20 000 different human proteins (an estimated 
89% of full-length human proteins) and a set of different path-
ogen protein arrays that all cover the majority of the different 
pathogen’s proteins. Similar to oligonucleotide arrays, spotting 
high-density protein arrays demands the generation of indi-
vidual clones. Each of these clones expresses a different protein, 
but expression levels vary widely depending on the expression 
system, codon usage, background proteases, proper folding, 
post-translational modification, generation of inclusion bodies, 
and intrinsic stability of expressed proteins. Therefore, these 
“purified protein microarrays” are usually stored at −80 °C, and 
must be used directly after thawing. Plasmid or oligonucleotide 
arrays do not have these stability problems, which has sparked 
the idea of first producing an array of plasmids, double-stranded 
PCR bands, or mRNA that code for the different proteins, and 
then employ in vitro transcription/translation systems to pro-
duce the corresponding protein arrays on demand (reviewed 
by He et al.[129] and Yu et al.[130]) Different systems have been 
developed to capture in vitro translated proteins nearby their 
arrayed coding DNA. One system coarrays different PCR prod-
ucts, which all include a T7 promoter and a tag, for example, the 
his-tag with the capturing agent, e.g., Ni-NTA surfaces, before 
an in vitro transcription/translation system starts to translate 
the different DNA molecules to the corresponding proteins. 
Thereby, the newly formed proteins diffuse only a limited dis-
tance before they are trapped by the capturing agent.[131] This 
elegant approach offers some clear advantages: arraying DNA 
molecules is a standard technology by now; these arrays are 
stable when stored over long time periods; usually in vitro trans-
lated proteins are less prone to aggregation; and a wide variety 
of different in vitro transcription/translation systems are avail-
able, for example, from E. coli, yeast, and rabbit reticulocytes, 
to mention a few. Using such an approach, Hufnagel and co-
workers[132] translated the proteome from the bacterial pathogen 
Chlamydia trachomatis into protein arrays to find immune domi-
nant antigens in infected women. They tested the quality of 
their in vitro translation process by staining two different N- and 
C-terminally added tags in every expressed protein, and, indeed, 
thereby they could show that nearly all of the PCR fragments 
yielded full-length proteins. The pathogen they scrutinized is a 
nicely example of the strength of protein-array method: it was 
suspected before that C. trachomatis infection and cervix carci-
nomas influence each other, but it was not known if there was a 
differential humoral immune response, and which of the patho-
gen’s proteins were differentially targeted. Using their arrays, 
they could clearly define C. trachomatis proteins that diagnose 
general infections, persistent infections, or an additional cer-
vical cancer. A variant of this method has been developed by 
LaBaer and co-workers. They coined the expression “nucleic 
acid programmable protein array” (NAPPA) for a method that 
would further limit lateral diffusion of in vitro translated pro-
teins. They structured the glass slide with different biotinylated 
coding plasmids that were captured and fixed at the spotting 
site by immobilized avidin. Thereby, they could add the in vitro 
transcription/translation system without diffusing the different 
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plasmids. Again, in vitro translated proteins were captured near 
their coding DNA via an expressed GST-tag, this time using an 
anti-GST tag antibody.[133] Yet another method transcribed dif-
ferent mRNAs from a library of plasmids, and spotted these dif-
ferent mRNAs onto a glass slide, where they were captured via 
a single-stranded DNA that hybridized to the mRNA’s 3′-end. 
An in vitro translation system was then used to translate the 
different mRNAs at “their” spots to a protein. Tao and Zhu 
employed a brilliant trick to fix the in vitro translated proteins 
directly to aforementioned single-stranded DNA: When reaching 
the RNA/DNA hybrid region, the ribosome stalls and transfers 
the nascent protein to a puromycin that was coupled before to 
the single-stranded DNA.[134] Early reviews from the pioneers in 
protein arrays were given by Walter and co-workers[135] and Zhu, 
Snyder, Sutandy, and co-workers.[136]
Smith[137] developed the phage display technique to fuse the 
to-be-expressed gene to a protein that is anchored on the phage’s 
surface. Thereby, the expressed protein or peptide carries its 
own gene as a backpack. Meanwhile, and commercialized by 
Dyax Corp., peptide libraries are available that display billions 
of different peptides that could be screened for binders. Finally, 
McCafferty et al. and Breitling et al. varied that approach to dis-
play billions of different antibody fragments on a phage[138] or 
phagemid[139] to screen for recombinant antibodies. In 2018, 
George P. Smith and Gregory Winter were awarded the Nobel 
prize for these achievements. However, the focus of this review 
is on highly parallelized and miniaturized chemical synthesis, 
and phage display has been reviewed elsewhere.[140]
Ronald Frank invented peptide arrays some 30 years ago.[141] 
In 1988, small pieces of paper were immersed consecutively 
in the 20 different solutions that contained the different 
building blocks for peptide synthesis to generate unique pep-
tides per piece of paper with only 20 different solutions, and 
in 1990—similar to Edwin Southern’s invention of oligonu-
cleotide arrays—he modified that approach by spotting these 
20 different Fmoc-amino acid pentafluorophenol (Pfp)-esters in 
N-methyl-2-pyrrolidon (NMP) at discrete locations onto a larger 
piece of paper that was derivatized with amino groups.[141c]
All the other processing steps were identical to standard Mer-
rifield synthesis: acetylation of the residual, unreacted amines 
was carried out with 2% acetic anhydride in DMF, and Fmoc-
deprotection with 20% piperidine in DMF. Thereby, Ronald 
Frank’s SPOT synthesis technique supplied the scientific com-
munity with high-quality peptide arrays, even though the level 
of miniaturization was moderate with only 25 spots per cm2.[141b] 
This technique dominated the field of peptide arrays for the next 
20 years. Compared to phage display it had two decisive advan-
tages: binding peptides could be immediately identified, and, 
contrary to phage display, it was easy to also build in unnatural 
building blocks, as well as other organic compounds.[141a] In 1993, 
the first SPOT-synthesizer (ASP222, 25 000 spots on 30 cm × 
30 cm) was commercialized by ABIMED Analysen-Technik, 
making array synthesis feasible to any research laboratory.[141a] 
Interestingly, although patented as early as 1994,[142] and con-
trary to oligonucleotide arrays, high-density peptide arrays that 
were in situ synthesized with an inkjet printer did not mate-
rialize for a long time period. Only very recently, Lam and 
co-workers published the combinatorial synthesis of peptide 
arrays with the help of a modified inkjet printer.[143]
Still, high-density, high-quality peptide arrays are needed for 
many different applications, especially when precious biological 
samples are only available in low quantities. To name a few: 
peptide arrays were used to find binding partners for patient- 
and for monoclonal antibodies,[60,144] interaction partners for 
double-stranded DNA,[145] metal ions,[146] to detect enzyme 
activity,[147] and cell adhesion (Figure 7).[148] In order to detect 
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Figure 7. Applications for peptide arrays. A) Interactions via metal ions, cells and DNA. B) Enzyme activity such as phosphorylation via measuring 
kinase activity. C) Epitope mapping and visualization. D) Validation of antibody peptide interactions. E) Substitution analysis. C–E) Reproduced with 
permission.[153] Copyright 2017, Wiley-VCH.
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these biological activities, for example, radioactivity,[148b,149] 
fluorescence spectroscopy,[148b,150] surface plasmon resonance, 
and MALDI-MS[147a] were used. To generate such high-density 
arrays, individual peptides were synthesized by SPOT synthesis 
in a low-density format and with amino-derivatized cellulose as 
solid support. Next, individual peptides were solubilized by par-
tially degrading the cellulose support before they were spotted 
in densities of up to 10 000 peptides per cm2.[62b,151,152]
Due to the cellulose moieties, these peptides were easily 
immobilized onto a glass surface by physical absorption.[141a,154] 
Alternatively, biological interactions (biotin/streptavidin[155] 
or avidin/biotin[156]) or covalent linkage (amine/aldehyde,[157] 
maleimide/thiol,[158] or amine/carboxy[159] chemistry) were used 
to tether these peptides to a surface and in array format. When 
synthesized by SPOT synthesis, chemical costs are estimated 
to be ≈1€ per peptide. Spot sizes of 100 pL were achieved by 
Pan and co-workers[160] with a printing platform that integrated 
microfluidic elements. In 2018, the group[161] presented an 
automated microdisk array preparation and screening plat-
form that allowed them to synthesize 2500 peptides per 15 cm2. 
The different reaction sites all form individual reservoirs that 
are supplied with the different amino acid building blocks via 
microfluidic channels (30 nL per cycle). As proof of concept, 
Pan and co-workers synthesized a peptide library and inves-
tigated the interaction of integrin proteins with the printed 
peptides.
In 2018, Atwater, Mattes, and co-workers[162] proved that 
very high-density peptide arrays indeed could be in situ syn-
thesized by preparing a peptide array with a pitch of 40 µm 
(62 500 per cm2) via microchannel cantilever spotting (µCS). 
However, µCS and other known printing technologies (e.g., 
dip-pen nanolitho graphy,[163] or polymer-pen lithography)[164] are 
too slow to produce affordable very high-density peptide arrays.
Legutki and co-workers[90] and others[165] combined the 
approach from Fodor and co-workers with the photoacids that 
were introduced by Pellois and co-workers[62a,81] and with mask-
less photolithographic techniques[62b,165] to synthesize very high-
density peptide arrays. Moreover, the company LC Science[166] 
commercializes such peptide arrays (30 000 per chip). It should 
be mentioned that the use of photoacids to cleave standard pro-
tecting groups comes with another drawback: it is difficult to 
remove the locally generated acids without hampering neigh-
boring synthesis sites. Therefore, several of these modern 
lithographic synthesis methods use sophisticated microfluidic 
systems to remove light-generated acids in the z-direction away 
from the synthesis sites. Another challenge is to demonstrate 
the quality of peptides in these very high-density peptide arrays. 
Legutki and co-workers[90] did that by MALDI-MS-imaging.
These very high-density peptide arrays have some very big 
advantages compared to phage display techniques. While it is 
very difficult to do phage display with posttranslational modified 
peptides—that seem to play a role especially in autoimmune 
diseases—Price and co-workers[167] synthesized silicon-based 
peptide arrays with 10 000 posttranslational modified pep-
tides for mapping antibody-binding sites. Legutki and co-
workers[90] synthesized 660 000 peptides per cm2. If stained 
with patient serum, these are so many peptides that simply, 
by chance, many of the patient’s antibodies will find a binding 
partner. Legutki and co-workers[90] and others[152b,165b,168] used 
these arrays to correlate found “immune signatures” with the 
patient’s diseases to eventually get a clue as to the cause of the 
investigated disease.
Experiments of this type will certainly pave the way for the 
commercial success of peptide arrays that still considerably lags 
behind oligonucleotide arrays. Currently, such arrays are either 
too expensive due to low density, or the quality of lithographic 
synthesized arrays is questionable. Therefore, the Breitling 
group developed yet another method to synthesize high-density 
and high-quality peptide arrays.
This solid-material-based synthesis method[61,144,169] employs 
a matrix material that is solid at room temperature with the 
different amino acid building blocks embedded within. Solid 
materials do not spread or diffuse laterally on a surface. If 
compared to spotting tiny liquid droplets, it is much easier to 
structure a surface with small spots of different solid mate-
rials. Moreover, chemicals that are embedded within these 
solid materials do not diffuse, and these spots do not evapo-
rate, which gives an experimenter plenty of time to complete 
the structuring without the fear that solvents will evaporate or 
some of the building blocks will start to couple to the surface 
before the structuring is completed. Another big advantage is 
that the employed matrix material obviously shields quite reac-
tive chemical building blocks from decay when stored in solid 
form.[169b] The basic trick of solid-material-based synthesis is 
simple: only when the structuring with the different chemical 
building blocks is completed, a heating step suddenly mobilizes 
hitherto immobilized amino acid building blocks for all of the 
reaction sites at once. They are then free to diffuse to the solid 
support where they couple to free amino groups on the solid 
support (Figure 8).
There are many different ways to structure a solid support 
with different solid materials. One approach employed the pixel 
electrodes of a computer chip to either attract or repel charged 
“amino acid particles” from an aerosol. Thereby, peptide arrays 
with 40 000 different peptides per cm2 were synthesized.[169a] 
Even more peptides could be synthesized when first spreading 
a particle layer over the solid support, and then melting and 
gluing these particles with single laser pulses at selected areas 
to “their” synthesis sites.[61b] However, neither of these two 
methods led to a commercial product. Much more successful 
in this respect was another approach that used a 24-color laser 
printer to deposit the different amino acid particles at their des-
ignated synthesis sites.[169b] These laser-printed peptide arrays 
have a density of 1000 peptides per cm2. They are commercial-
ized by PEPperPRINT GmbH. The machine is equipped with 
24 printing units, each containing another type of amino acid 
particle. The printing mechanism in this machine is based on 
a standard laser-printing process: Each printing unit has an 
organic photoconductor drum (OPC) that is heavily charged 
with the help of a corona that repels triboelectrically charged 
amino acid particles. This OPC drum is illuminated at selected 
areas with a light source, in order to neutralize selected areas 
on the surface of the OPC drum. The amino acid particles then 
stick to these neutralized areas. Next, the resulting particle pat-
tern is transferred to a solid functionalized carrier, once again 
employing a strong electrical field. At the center of this machine 
is the light source that is used to generate the electrostatic pat-
tern on the OPC drum: it consists of a ≈20 cm long row with 
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10 000 individually steerable light-emitting diodes (LEDs) from 
the OKI C7400 color laser printer.
Yet another method to structure a solid support with matrix-
embedded amino acid building blocks was published by 
Loeffler and co-workers in 2016.[61a] This time, the same solid 
material that was used in the “peptide laser printer” was spin-
coated onto a thin Kapton foil as a 1–2 µm thin material layer. A 
2D laser scanning system was developed to illuminate selected 
areas on this “donor foil” with individual laser pulses. These 
pulses are absorbed by the Kapton foil, and, thereby, “trans-
lated” to site-specific heat packages that propagate to the mate-
rial layer on the surface to site-specifically “punch out” tiny 
material spots from the material layer. This material is depos-
ited as a thin layer onto an acceptor slide where peptide syn-
thesis takes place, with a maximal distance of 40 µm between 
donor slide and acceptor slide. With this approach, Löffler and 
co-workers synthesized arrays with >17 000 peptides per cm2 
and in good quality. Moreover, this method is especially easy 
to automate: donor and acceptor slides are easily exchanged 
by a robot, while the structuring is done by simply writing a 
second pattern with the 2D laser-scanning system that would 
transfer a second material on top or next to previously trans-
ferred materials.
At least for those materials that were analyzed in more detail, 
Löffler, Förtsch, and co-workers realized that transferred mate-
rial spots were nanoscale in the z-direction (Figure 9). More-
over, the energy of the laser pulse determines the amount of 
transferred materials. In other words, the amount of chemical 
building blocks that are deposited in their respective synthesis 
sites is easily tuned by adjusting the laser’s pulse energy, and 
this can be done with many different chemicals, and in any 
combination. Indeed, Löffler and co-workers[61a] clearly showed 
that a nanoscale activation layer (N,N′-diisopropylcarbodiimide 
(DIC) and hydroxybenzotriazole (HOBt)) stacked over 
nanoscale matrix-embedded nonactivated Fmoc-protected 
amino acid building blocks could couple these in situ activated 
amino acids to the solid support. In 2018, Mattes et al.[170] 
used the 2D laser-scanner system to stack up to four different 
nanoscale material layers on top of each other to generate 
peptoid arrays via the monomer and submonomer method. 
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Figure 8. Solid-material-based synthesis. A) A laser printer deposits toner particles consisting of a matrix material, OPfp-activated and Fmoc-protected 
amino acid derivatives, at designated synthesis sites. After deposition of all 20 amino acid particles (example illustrated with three colors for three dif-
ferent amino acids) of each layer, these are all melted at once to let hitherto-immobilized monomers diffuse and couple to the surface. After coupling, 
residues of the matrix material are washed away, remaining coupling sites are capped and the growing peptide chain is deprotected to be prepared 
for the next layer to be coupled. B) View of the peptide laser printer and a detailed look at its 24 printing units. A) Reproduced with permission.[169b] 
Copyright 2008, Wiley-VCH.
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Upon melting, Fmoc-protected N-substituted glycine deriva-
tives, embedded in matrix material, diffused through three 
nanometer-thin layers into an immobilized polymer film on a 
glass slide. These nanolayers harbored different chemicals to 
activate the building blocks for peptoid synthesis during their 
passage through these activation layers. The verification of pep-
tides was done via MALDI-MS imaging. The necessary MALDI 
matrix material was laser-transferred to ablate a thin amount 
of the matrix on top of the peptide spot to generate good m/z 
signals. Future experiments certainly will try to implement this 
approach beyond peptide, peptoid synthesis, and solid-phase 
synthesis, for example, by doing multistep one-pot reactions in 
many different reaction sites that are isolated from each other 
with the help of hydrophilic/hydrophobic patterns.
3.5. Microfluidics
Microfluidic devices find wide applications in nanoparticle syn-
thesis,[171] organic chemistry,[172] combinatorial chemistry,[161,173] 
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Figure 9. Laser-induced nanoprinting (in the z-direction). A) View of the nano-3D-printer with its different functional units (AOM = acousto-optic mod-
ulator). B) A coated donor slide is positioned over an acceptor substrate. Next, single laser pulses from a 2D laser scanning system “punch out” tiny 
material spots that are transferred to the acceptor slide. Simply by repeating this processing step with additional donor slides leads to the structuring 
of the acceptor slide with many different nanolayers that comprise polymer-embedded, and, thereby, stabilized chemicals. These solid nanolayers are 
stacked by the robot in freely chosen combinations and stoichiometry. C) When melted by solvent vapor in a controlled atmosphere, extremely miniatur-
ized chemical reactions are started in the array format. Removal of solvent vapor stops these chemical reactions, and additional chemicals can be added 
to do multistep one-pot reactions. MALDI MS imaging can be used to analyze reaction products. D) Transferred material spots are nanoscale (measured 
with vertical scanning interferometry). The transfer of a first, a second, a third, and a fourth layer of matrix material (the material that is used to embed 
Fmoc-amino-acid building blocks) is shown. Stacked layers from 1×, 2×, 3×, 4× printing are depicted in different colors to highlight added material. 
A) Reproduced under the terms of the CC-BY 4.0 Creative Commons Attribution International License (http://creativecommons.org/licenses/
by/4.0/).[61a] Copyright 2016, Springer Nature. D) Provided by and used with the permission of Dr. Tobias Förtsch.
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and cell[174] and biological[175] assays. In 2006, Whitesides[176] 
predicted a prominent role for microfluidics in miniaturizing 
chemical reactions, but this prediction has not yet come true. 
Indeed, nowadays, microfluidics chips exist that reliably generate 
and move thousands or even millions of monodisperse drop-
lets in the micrometer range. These oily droplets are immersed 
in an immiscible aqueous carrier medium (or vice versa) 
to create many confined microreactors, whereby the interface 
is usually stabilized by surfactants. They can be loaded with 
building blocks for chemical synthesis, reagents for analytical 
assays, or even cells for biological assays (Figure 10a). These 
droplet-based microreactors have some unique features when 
compared to batch chemical synthesis in a flask: they are tiny 
(≈10 µm-sized droplet translates to a reaction volume of ≈1 pL), 
which translates to low costs per chemical reaction. Moreover, 
better heat and mass transfer should lead to faster chemical 
reactions. Finally, scientists have developed methods to fuse 
selected droplets, which could be used to start a chemical reac-
tion. There are a few drawbacks though: surfactants restrict the 
use of microreactors; for example, a reaction product should 
not destabilize the interface, nor should the surfactant interfere 
with the chemical reaction. Another restriction comes from the 
surrounding liquid that should not be a solvent for any of the 
reaction partners or products.
Indeed, in digital microfluidics,[177] individual microdroplets 
can be manipulated via electric voltage such as droplet transfer, 
droplet mixture, and separation in multistep processes. Such a 
technique could be used to freely combine different building 
blocks for chemical synthesis.[178] However, to date, digital 
microfluidics is not yet suitable to setup thousands of different 
miniaturized reaction mixtures, due to the too slow handling of 
thousands of droplets in a short time period.
Obviously, one important feature is still missing: procedures 
are needed to first generate, and then store many different 
kinds of droplets in the microfluidic system, before different 
kinds of droplets with their different chemicals inside are fused 
to initiate many different chemical reactions. Kaminski and 
Garstecki[179] proposed a concept to do that: larger reservoirs 
inside the microfluidic system could be filled with the dif-
ferent chemicals dissolved in a suitable solvent. The individual 
reservoirs are then used to form small droplets that are trans-
ported to the reaction site, where they are fused with other 
droplets to start the chemical reaction.[180] However, since the 
chemicals inside influence the droplet’s surface tension, it is 
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Figure 10. Microfluidics offers all the elements that are needed to do many extremely miniaturized chemical reactions while efficiently shielding reac-
tive chemicals from the environment. A) Cross-junctions or T-junctions can generate monodisperse droplets that harbor exactly defined amounts 
of chemicals. B) Selected microdroplets can be fused to start a chemical reaction in a defined reaction sphere, before they are moved to a “parking 
place.” C) In-chip-integrated microactuators and valves will allow the movement of and sort selected microdroplets at will. D) Reaction spheres can be 
monitored over time by spectroscopic methods. E) Reaction products can be patterned onto a slide for MALDI-MS imaging.
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difficult to create droplets of similar size from different reser-
voirs and using only one pressure pump.
This difficulty could be solved by the integration of several 
microactuators inside the chip.[181] These actuators could tune 
the applied pressure for the individual reservoirs to generate 
monodisperse droplets from each reservoir. The near future 
will certainly see chips with extremely miniaturized pumps 
that are integrated into microfluidic systems,[182] and one appli-
cation certainly will be to form droplets of defined sizes from 
different reservoirs inside the microfluidic system. Fusing two 
of these droplets would then create a unique mixture of chemi-
cals to start a chemical reaction (Figure 10b). Next, one of the 
in-chip micropumps could move these fused droplets to a side 
branch of the microfluidic system and store them there to let 
the chemical reaction proceed (Figure 10c). For monitoring 
the reaction spheres, spectroscopic methods can be used 
(Figure 10d). Finally, the pump could resume its activity; for 
example, to spot the individual droplets in array format to a 
gold-covered glass chip, add the MALDI matrix, and determine 
the masses of synthesized molecules by MALDI-MS imaging 
(Figure 10e).
Currently, most microfluidic chips are made of an elastomer 
such as poly(dimethylsiloxane) (PDMS)[183] or off-stoichiometry 
thiol-enes (OSTEs).[184] Compared to sophisticated chip techno-
logy, such PDMS chips are easily manufactured,[185] and, 
therefore, have dominated the research area in recent years. 
These PDMS-based chips are not rigid, which translates to 
significant pressure decline over distance. That in turn makes 
it difficult to guarantee repeatable flow conditions in sophisti-
cated chip designs. In addition, the completely different ways 
to manufacture them make them incompatible with the in-
chip-micropumps that were described by Uhlig et al.[182] More-
over, PDMS is unstable for many organic chemicals, which 
certainly makes borosilicate glass microfluidic chips the prefer-
able choice for chemical synthesis. These glass chips are syn-
thesized via wet[186] or dry[187] etching, which are procedures 
that are available to only a few laboratories. Meanwhile such 
chip designs are commercially available, but their production 
used to be too expensive to rival the flexible design of PDMS-
chips. In 2016, Kotz et al.[188] invented a procedure to print 
glass, and, thereby, opened a route to easily design and man-
ufacture glass-based microfluidics systems that is as flexi ble 
as the production of PDMS chips. The combination with a 
method to store different types of microdroplets, for example, 
by printing microfluidic channels onto a chip with integrated 
micropumps, means that these glass-chips indeed could be 
used to set up tens of thousands extremely miniaturized chem-
ical reactions.
4. Conclusion and Outlook
We have described selected examples in the automation and in 
the miniaturization of chemical synthesis. We think that the 
future will see a merger between these two different trends, i.e., 
automated synthesis of many different chemicals and in many 
miniaturized reaction sites. While miniaturization of chemical 
reactions was initially driven by a desire in the life sciences 
to synthesize and analyze many different oligonucleotides or 
peptides, the driving forces that have advanced the automation 
of chemical reactions are manifold.
4.1. Automation in Chemistry
In the past, chemical companies invested into the automation 
of chemical reactions to improve the time and cost efficiency 
of chemical synthesis. This was and is important to meet the 
need for new compounds and large libraries of different com-
pounds that are not available with reasonable effort by standard 
synthesis techniques. Other benefits of advances in automa-
tion techniques are an improvement of safety standards, which 
is especially important for reactions that include hazardous 
substances and an improvement of the reproducibility of the 
reactions in contrast to a manual synthesis. In particular, the 
latter arguments are relevant in academia as well, and have 
led to developments and applications of automated synthesis 
in universities. Especially flow chemistry gives the opportunity 
to do an upscaling of synthesized chemicals in an automated 
fashion, which was yet another reason that drove automation 
in chemical synthesis. While in the past, automation in par-
ticular in pharmaceutical research was driven due to the need of 
chemical compounds for biological screenings, the past devel-
opments are now ready to be used and advanced by the need of 
chemical compounds for materials development. The growing 
numbers of cheminformatics tools and prediction models allow 
the virtual design and evaluation of virtual compound libraries 
that are supposed to provide suitable structures for future devel-
opments. For those new virtual libraries, novel retrosynthesis 
models allow the automated analysis of the most suitable reac-
tion paths without the need for a design by a chemistry expert. 
In combination, these AI-driven developments enforce the need 
for efficient synthesis methods and automation for materials 
sciences in the future to be able to evaluate the virtually pre-
dicted applications. At the moment, the necessary amount of 
chemical substance for the testing of properties in materials sci-
ences is still high and does not correspond to the substance effi-
ciency that has been achieved in biological screenings in the last 
decades. Therefore, to date, automation techniques resulting in 
the isolation of substances in multi-milligram to gram scale are 
of high importance for materials science. In future, approaches 
in miniaturization of the testing procedures and techniques will 
most likely result in a drastically reduced amount of necessary 
substance for a validation and evaluation of properties. Minia-
turization strategies that are already known for the synthesis of 
peptides, oligonucleotides, sugars, and other substances or are 
in development at the moment may have high impact on the 
future development of materials sciences.
4.2. Miniaturized Chemical Synthesis
Some very impressive examples from the life sciences prove 
that chemical synthesis indeed can be drastically miniatur-
ized: i) based on the seminal work of Edwin Southern and 
Stephen Fodor, nowadays whole genomes are assembled from 
synthesized oligonucleotides, and ii) based on the work of 
Ronald Frank, we are not too far away from translating whole 
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proteomes into arrays of overlapping peptides, while others 
have employed cells to synthesize whole genome protein arrays. 
Certainly, we can expect this type of approach to be used in 
the near future to in situ synthesize arrays that display tens of 
thousands of oligosaccharides, peptides, proteins, peptoids, and 
other oligomers that are of interest for the life sciences. Such 
arrays can be used, for example, to synthesize whole genomes, 
or pinpoint antibody-binding structures that are especially good 
vaccine candidates.
However, simple screening for binding antibodies or com-
plementary cDNA—and ignoring sites where synthesis failed—
is not sufficient if the task is to find and optimize novel syn-
thesis routes. For such a task, an experimenter must first find 
optimized conditions for the different steps in a synthesis 
route, and then combine several of these synthesis steps; for 
example, in solid-phase synthesis of oligomers, or in sophis-
ticated multistep one-pot reactions. Clearly, the experimenter 
must find out which of the different reaction conditions gave 
the desired product(s) for the different synthesis steps. Other-
wise, false-positive reaction conditions would drastically aug-
ment the number of erroneously designed multistep reactions, 
and, thereby, invalidate the advantages of high-throughput 
experimentation with miniaturized synthesis sites. There-
fore, one important task for highly parallelized and miniatur-
ized synthesis is to find out for thousands or even millions of 
reaction sites, if a molecule of the expected molecular weight 
has been synthesized or not. Indeed, the seminal work of Lin 
et al.[3d] showed that MALDI-MS could deliver that information 
for miniaturized chemical reactions.
Another task is to mix different chemicals in freely chosen 
and exactly tunable stoichiometry, and then have them reacting 
for a defined time span. Doing that in extremely miniaturized 
chemical synthesis adds yet another challenge: reactive chemi-
cals must be shielded from the environment during the pro-
cessing steps. The nano-3D printer (Figure 9) and microfluidics 
(Figure 10) are especially suited to perform this task. The nano-
3D-printer stacks the different chemicals in solid, i.e., protec-
tive nanoscale layers on top of each other, and then starts the 
many different chemical reactions by either melting the solid 
material, or by adding solvent vapor in a controlled environ-
ment. Microfluidics can be used to create and fuse droplets 
with exactly defined size, which are used as miniaturized reac-
tion spheres that are efficiently shielded from the environment. 
A very charming feature of this approach is that all of these 
individual droplets can be analyzed by spectroscopic methods 
while still inside the microfluidic system. The recent invention 
of in-chip actuators that could be used as micropumps could 
supply the only thing that was missing so far: an easy method 
to store different sorts of droplets within the system before 
they are spotted to discrete sites on a glass slide to analyze the 
outcome of the different chemical reactions by MALDI-MS 
imaging.
Certainly, and similar to the life-sciences-driven approaches, 
the driver for miniaturized chemical reactions will be screening 
for function. The reason is simple: funding agencies and 
venture capital will increasingly fund only those projects that 
promise to solve major challenges that our world faces in the 
near future. Nearly always chemistry is and will be needed to 
tackle these challenges as some important examples show that: 
i) for more efficient regenerative energy, we need to improve 
organic or inorganic solar cells, ii) to transform our transpor-
tation systems, we need novel batteries and fuel cells, iii) to 
synthesize all kinds of raw materials (methanol, sugar, building 
blocks for polymers), we need novel catalysts that directly har-
vest the energy of the sun, and iv) for energy-efficient light-
emitting diodes, we need innovative chemistries. All these 
examples demand that chemistry mates with the material sci-
ences to synthesize as many different molecules as possible 
and screen them for function, which can only be done in min-
iaturized form.
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